文献速递甲状腺疾病

评估英国老龄化人群中左甲状腺素使用的心血管效应(ACEL-UK):队列研究

Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom Population (ACEL-UK): Cohort Study.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该回顾性队列研究利用英国初级保健数据,纳入53899例50岁以上亚临床甲状腺功能减退症患者,比较处方与未处方左甲状腺素者的结局。左甲状腺素治疗与心血管事件风险降低相关(HR 0.91),但与骨事件风险升高(HR 1.21)和全因死亡风险升高(HR 1.17)相关。作者认为需权衡心血管获益与骨骼及死亡风险。

要点

  • 50岁以上亚临床甲减患者中,左甲状腺素治疗与心血管事件风险降低相关(HR 0.91)。
  • 左甲状腺素治疗与骨事件风险升高(HR 1.21)和全因死亡风险升高(HR 1.17)相关。
  • 作者认为处方左甲状腺素时需考虑、缓解并讨论这些风险。

核心结论

  • 作者认为,老年亚临床甲减患者使用左甲状腺素存在心血管风险潜在获益与骨骼健康及死亡风险不良关联之间的权衡。
  • 作者指出,在考虑对老年亚临床甲减患者处方左甲状腺素时,需考虑、缓解并讨论这些风险。

研究设计与样本

  • 回顾性队列研究,使用英国健康改善网络(Health Improvement Network)初级保健数据。
  • 纳入53899例50岁以上亚临床甲减患者,基线中位年龄67岁(IQR 59-76岁),女性占68.5%,中位TSH 4.6 mU/L(IQR 4.1-5.4 mU/L)。
  • 19952例(37%)接受左甲状腺素治疗,33947例(63%)未接受。
  • 中位随访10年(IQR 5.5-10.0年),采用校正相关因素的时间依存风险比(HR)。

主要发现

  • 左甲状腺素治疗与心血管事件风险降低相关(HR 0.91;95%CI 0.87-0.97;P<.001)。
  • 左甲状腺素治疗与骨事件风险升高相关(HR 1.21;95%CI 1.14-1.28;P<.001)。
  • 左甲状腺素治疗与全因死亡风险升高相关(HR 1.17;95%CI 1.13-1.22;P<.001)。

临床怎么用

  • 作者认为,在考虑对老年亚临床甲减患者处方左甲状腺素时,需考虑、缓解并讨论心血管获益与骨骼及死亡风险之间的权衡。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Thyrotropin (TSH) levels tend to rise with age, but standard reference intervals do not reflect this, potentially leading to overdiagnosis of subclinical hypothyroidism (SCH) and excessive levothyroxine (LT4) prescriptions in older adults. OBJECTIVE: This work aimed to compare outcomes in adults older than 50 years with SCH who were either prescribed or not prescribed LT4. METHODS: A retrospective cohort study was conducted using data from UK Primary Care patients from the Health Improvement Network. The primary outcome was cardiovascular (CV) events (angina, myocardial infarction, peripheral vascular disease, stent procedures, or stroke). Secondary outcomes included bone events (fragility fractures or osteoporosis) and all-cause mortality. Time-varying hazard ratios (HRs) adjusted for relevant factors were estimated. RESULTS: This study included 53 899 patients (baseline median age 67 years (interquartile range [IQR]: 59-76 years); 68.5% female; median TSH 4.6 mU/L (IQR: 4.1-5.4 mU/L). Median follow-up duration was 10 years (IQR: 5.5-10.0 years). Of these, 19 952 (37%) received LT4 and 33 947 (63%) did not. LT4 therapy showed a protective effect against CV events (HR: 0.91; 95% CI, 0.87-0.97; P < .001) but increased risk of bone events (HR: 1.21; 95% CI, 1.14-1.28; P < .001) and all-cause mortality (HR: 1.17; 95% CI, 1.13-1.22; P < .001). CONCLUSION: Our data suggest that LT4 therapy in older individuals with SCH is associated with a trade-off between the potentially beneficial effect on CV risk and the deleterious relationship with bone health and mortality risk. These risks need to be considered, mitigated, and discussed when LT4 therapy is being deliberated in older patients with SCH.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Holley M, Razvi S, Maxwell I, et al. Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom Population (ACEL-UK): Cohort Study. J Clin Endocrinol Metab. 2025. PMID: 40179252. doi:10.1210/clinem/dgaf208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。